LONDON (Reuters) - AstraZeneca Plc faces a delay in marketing its asthma drug Symbicort to young children in the United States after regulators asked for more information, dealing a blow to an ...
Wilmington, DE – May 20, 2008 – A new 12-week study2examined safety and efficacy measures of the maintenance combination asthma therapy, SYMBICORT® (budesonide ...
Wilmington, DE – June 4, 2008 – AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug ...
Government health advisers recommended restrictions Thursday on some long-acting asthma drugs, although not Advair, a top-selling medication. Outside experts advising the Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results